Core Viewpoint - The company has approved a change in the use of raised funds to enhance operational efficiency and align with its strategic development needs, specifically reallocating funds for acquisitions in the pharmaceutical retail sector [1][6][15]. Fundraising Overview - The company raised a total of RMB 974.56 million by issuing 60.01 million shares at RMB 16.24 per share, with a net amount of RMB 879.45 million after deducting issuance costs [1][2]. - The company has utilized RMB 25.72 million for marketing network construction and has remaining funds of RMB 26.46 million for this project as of May 8, 2025 [6][7]. Changes in Fund Usage - The company has decided to reallocate RMB 130.73 million from the marketing network construction project to acquire stakes in three pharmaceutical retail companies in Fujian and Zhejiang provinces [5][7]. - The new acquisitions include 46.01% of Yangzu Hui Min Pharmaceutical Chain for RMB 13.34 million, 46.01% of Haihua Pharmaceutical for RMB 12.51 million, and 70.01% of Tonglu Yishengtang for RMB 6.83 million [7][11]. Strategic Rationale - The change in fund usage is aimed at improving market share and brand influence in the East China region, aligning with the company's long-term strategic plan [7][9]. - The acquisitions are expected to enhance operational efficiency and market presence, leveraging the local advantages of the target companies [9][10]. Approval Process - The change in fund usage was approved by the company's board of directors, supervisory board, and audit committee, ensuring compliance with relevant regulations [6][15][16]. - The independent directors and sponsor have also confirmed that the decision aligns with the company's operational needs and does not harm shareholder interests [15][16][17].
华人健康: 关于变更募集资金用途的公告